News
XERS
1.765
-0.84%
-0.015
Weekly Report: what happened at XERS last week (0415-0419)?
Weekly Report · 2d ago
Validea James P. O'Shaughnessy Strategy Daily Upgrade Report - 4/20/2024
NASDAQ · 4d ago
Strength Seen in MediWound (MDWD): Can Its 14.3% Jump Turn into More Strength?
NASDAQ · 04/17 11:24
Pleasing Signs As A Number Of Insiders Buy Xeris Biopharma Holdings Stock
Xeris Biopharma Holdings, Inc. Insiders have been buying shares in the last year. The biggest single purchase by an insider was US$55k worth of shares at a price of US$1.95 per share. In the last twelve months Xeris Biophilearma Holdings insiders were buying shares, but not selling. It's important to look at the insider transactions of a company. There's been some buying of shares in Xeris biopharm Holdings. The company owns about US$12m of shares. You can see the insider buying and selling of shares over the last decade.
Simply Wall St · 04/17 10:20
Weekly Report: what happened at XERS last week (0408-0412)?
Weekly Report · 04/15 09:06
Weekly Report: what happened at XERS last week (0401-0405)?
Weekly Report · 04/08 09:07
XERIS PHARMACEUTICALS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 04/03 20:05
Weekly Report: what happened at XERS last week (0325-0329)?
Weekly Report · 04/01 09:07
Xeris Biopharma: Checking-In On One Of My 'Top Ideas'
Xeris Biopharma has not yet achieved cash flow breakeven and may no longer be a "Top Idea" in the Compounding Healthcare Investing Group. Xeris has three approved products and a strong pipeline, with potential for market penetration and revenue growth. Risks include competition from larger companies and the FDA approval of a generic version of one of Xeris' products.
Seeking Alpha · 03/30 05:28
Xeris gains as Oppenheimer highlights drug technology
Xeris Biopharma (NASDAQ:XERS) traded higher on Thursday after Oppenheimer highlights drug technology. The company's drug formulation technologies, XeriSol and XeriJect, allow for convenient, cost-effective drug storage. XERS's experimental therapy, XP-8121, has a potential $1B+ sales opportunity.
Seeking Alpha · 03/28 17:11
Xeris Biopharma Initiated at Outperform by Oppenheimer
Dow Jones · 03/28 11:02
Oppenheimer Initiates Coverage On Xeris Biopharma Holdings with Outperform Rating, Announces Price Target of $5
Benzinga · 03/28 10:51
ANGI, MLKN and KOD are among after hour movers
On the Move ANGI, MLKN and KOD are among after hour movers. ATHA, XERS, KOD, PHAT, INZY, NAMSW, LENZ are among the day's losers. MillerKnoll is down 13%.
Seeking Alpha · 03/27 20:50
Weekly Report: what happened at XERS last week (0318-0322)?
Weekly Report · 03/25 09:07
Weekly Report: what happened at XERS last week (0311-0315)?
Weekly Report · 03/18 09:07
Weekly Report: what happened at XERS last week (0304-0308)?
Weekly Report · 03/11 09:07
Analysts Offer Insights on Healthcare Companies: Applied Therapeutics (APLT), Xeris Pharmaceuticals (XERS) and Arcturus Therapeutics (ARCT)
Companies in the Healthcare sector have received a lot of coverage today. Applied Therapeutics, Xeris Pharmaceuticals and Arcturus Therapeutic have been recommended by analysts. Leerink Partners analyst Joseph Schwartz reiterated a Buy rating on AppliedTherapeutics. The company has an analyst consensus of Strong Buy for the stock.
TipRanks · 03/11 04:40
Analysts Are Updating Their Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Estimates After Its Full-Year Results
Xeris Biopharma Holdings, Inc. Reported revenues of US$164m in its annual report. The stock has since dropped 26% to US$2.35 following the release of the results. The company's revenue growth is expected to slow, but is still expected to grow faster than the industry. The consensus forecast for the company's revenues is for US$185.0m in 2024. However, the company also reported larger than expected losses of  US$0.45 per share.
Simply Wall St · 03/09 14:28
Xeris Biopharma Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 03/07 11:23
Xeris Biopharma Price Target Raised to $6.00/Share From $5.50 by HC Wainwright & Co.
Dow Jones · 03/07 11:23
More
Webull provides a variety of real-time XERS stock news. You can receive the latest news about Xeris Biopharma Holdings through multiple platforms. This information may help you make smarter investment decisions.
About XERS
Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which is focused on improving patients’ lives by developing and commercializing products across a range of therapies. It has three commercial products. Gvoke is a ready-to-use, liquid-stable glucagon for the treatment of severe hypoglycemia. Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome for whom surgery is not an option or has not been curative. Keveyis is the first therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of Primary Periodic Paralysis (PPP). It also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect. Its product candidate XP-8121, which is designed to be a once-weekly, small-volume, subcutaneous injection that bypasses the gastrointestinal tract and could avoid many therapeutic complications.